Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be ...

A global clinical trial is underway to evaluate two anti-inflammatory drugs as potential treatments for long COVID, aiming to ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Gosselies, Belgium Saturday, April 26, 2025, 16:00 Hrs [IST] ...

By using a compound derived from a Himalayan fungus and used for centuries in Chinese medicine as a jumping off point, ...

A new drug combination shows promise for colon cancer patients whose disease no longer responds to standard chemotherapy ...

Medtronic , a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption ...

Zealand Pharma begins patient enrolment in phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes: Copenhagen, Denmark Saturday, April 2 ...

Clarity, along with most Aussie biotech, has been caught in a double whirlwind: a sharp sell-off in US healthcare stocks and ...

Joseph Jacob, MD, discusses data from the phase 2b SunRISe-1 study, cohort 2, evaluating TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety ...